The American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) guidelines suggest that “Testing of DCIS for ER is recommended to determine potential benefit of endocrine therapies to reduce risk of future breast cancer, while testing DCIS for PgR is considered optional” [24]. This evidence concerns the gene PGR and ductal breast carcinoma in situ.